Tempest Therapeutics, Inc. (TPST)

Tempest Therapeutics' stock has experienced significant volatility in the past six months. In October 2023, the stock surged nearly 4000% following positive data from a Phase 1/2 study of TPST-1120, followed by a drop of over 50%. The stock price declined by 76.67% between January 10, 2025, and January 8, 2026. In November 2025, the company announced the acquisition of dual-CAR T programs from Factor Bioscience Inc. in an all-stock transaction. In January 2026, Tempest Therapeutics received a Nasdaq noncompliance notification.

As a clinical-stage biotechnology company without commercialized products, Tempest Therapeutics does not have traditional demand seasonality. Seasonality mentions typically refer to stock performance patterns rather than market demand for its therapeutic candidates, which are still in development.

Tempest Therapeutics is a clinical-stage oncology company focused on developing small molecule product candidates that combine tumor-targeted and immune-mediated mechanisms for cancer treatment. Key therapeutic candidates include TPST-1120, a PPARα antagonist in Phase Ib/II trial for advanced liver cancer, and TPST-1495, a dual antagonist of EP2 and EP4 receptors in Phase 1 for endometrial cancer and planned Phase 2 for FAP. The company is also developing an orally available inhibitor of TREX-1. In late 2025, Tempest acquired dual-CAR T programs from Factor Bioscience Inc., including TPST-2003, a CD19/BCMA dual-CAR T program.

Tempest Therapeutics is headquartered in Brisbane, California, United States. Its clinical development programs have an international reach, including a global trial for TPST-1120 and collaboration with F. Hoffmann-La Roche Ltd. The TPST-2003 program has plans for a BLA in China and a potential registrational study in the U.S., with Tempest holding global rights outside of China, India, Turkey, and Russia.

Tempest Therapeutics' brand reputation has been influenced by positive clinical developments and stock performance. Positive data from the Phase 1/2 study of TPST-1120 provided a temporary boost, but the stock's volatility and a consensus rating of "Reduce" indicate less favorable analyst views. The Nasdaq noncompliance notification could also negatively impact its corporate reputation.

The ownership structure of Tempest Therapeutics includes institutional, retail, and individual investors. Major institutional owners include Versant Venture Management, LLC, Vanguard Group Inc, Geode Capital Management, LLC, BlackRock, Inc., and Fmr Llc. Following the acquisition of Factor Bioscience, Factor's equity holders, particularly Matt Angel, Ph.D., became dominant strategic owners, representing approximately 65% of the total outstanding stock. Brad Bolzon owns the most shares among individual investors.